Frontier mental health research: psychedelics & drug studies

Key findings

• Some clinical trials reported that people given classic psychedelics, including LSD, had lower anxiety afterward, for example in cancer-related distress and some anxiety disorders. ^{15055 15068}
• Most modern LSD studies give the drug together with psychotherapy and careful preparation. The therapy and setting (called “set and setting”) are seen as part of the treatment. ^{15096 15065}
• The overall evidence is still limited. Many trials are small, use different methods, or mix drugs and therapy, so we cannot yet say LSD is a proven, widely tested treatment for anxiety. ^{15078 15085 15068}
• Classic psychedelics like LSD act mainly on a serotonin receptor called 5‑HT2A. Lab and animal studies also show these drugs can increase brain plasticity, meaning the brain’s ability to change connections. ^{15086 15050}
• Large reviews and recent clinical work report generally favorable safety profiles for psychedelics when used in controlled medical settings, but this does not mean there are no risks. ^{15135 15055}
• LSD and other psychedelics can cause hallucinations. In some people these effects can be intense and, rarely, lead to lasting perceptual or mental-health problems. ¹⁵⁰⁸⁰
• Biological markers tied to brain growth, such as blood levels of BDNF (a brain protein), have not shown clear consistent changes after psychedelic or psychoplastogen dosing in pooled human studies. That means we do not yet have a reliable blood test that proves how these drugs affect brain repair in people. ¹⁵¹²⁹
• Important gaps remain: many studies include few participants from non‑White groups, trial designs vary a lot, and researchers still debate how much the subjective psychedelic experience itself matters for the treatment effect. ^{15095 15078 15086}